7780 — Daiken Biomedical Co Balance Sheet
0.000.00%
- TWD13.89bn
- TWD8.85bn
- TWD1.36bn
- 54
- 15
- 32
- 20
Annual balance sheet for Daiken Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Equivalents | |||
| Cash and Short Term Investments | 244 | 287 | 1,140 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 53.5 | 71.5 | 94.2 |
| Total Inventory | |||
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 524 | 733 | 1,511 |
| Net Property, Plant And Equipment | — | 0 | 3.28 |
| Net Intangible Assets | |||
| Other Long Term Assets | |||
| Total Assets | 530 | 745 | 1,538 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Current Portion of Long Term Debt / Capital Leases | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 241 | 448 | 230 |
| Long Term Debt | |||
| Capital Lease Obligations | |||
| Total Long Term Debt | |||
| Total Debt | |||
| Total Liabilities | 303 | 498 | 231 |
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 227 | 247 | 1,307 |
| Total Liabilities & Shareholders' Equity | 530 | 745 | 1,538 |
| Total Common Shares Outstanding |